The possibility that modest elevations in the level of blood homocysteine (hyperhomocysteinaemia) could contribute to cardiovascular disease arose from investigation of patients with rare, severe homocysteine elevations caused by cystathionine β-synthase deficiency. Such patients often had thromboembolic events before the age of 30 years. Since the established cardiovascular risk factors could only partly account for the occurrence and severity of vascular disease in the general population, other risk factors had to exist, and homocysteine elevation seemed to be a possible candidate.
CarsonNAJNeillDW.Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Arch Dis Child1962; 37:503–513.
2.
CarsonNAJCusworthDCDentCEFieldCMBNeillDWWestallRG.Homocystinuria: A new inborn error of metabolism associated with mental deficiency. Arch Dis Child1963; 38:425–436.
3.
GerritsenTVaughanJGWatsmanHA.The identification of homocystine in the urine. Biochem Biophys Res Commun1962; 9:493–496.
4.
MuddSHLevyHLSkovbyF.Disorders of transsulfuration. In: ScriverCRBeaudetALSlyWSValleD (editors): The metabolic and molecular basis of inherited disease. 7th ed. New York: McGraw-Hill; 1995. pp. 1279–1327.
5.
CarsonNAJDentCEFieldCMBGaullGE.Homocystinuria: Studies of 20 families with 38 affected members. JAMA1965; 193:711–719.
6.
SchmikeRNMcKusickVAHuangTPollackAD.Homocystinuria: Clinical and pathological review of ten cases. J Pediatr1965; 193:711–719.
McCullyKS.Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol1969; 56:111–128.
9.
FrantzenFFaarenALAlfheimINordheiAK.Enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem1998; 44:311–316.
10.
MuddSHSkovbyFLevyHLPettigrewKRWilckenBPyeritzRThe natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet1985; 37:1–31.
11.
CelermajerDSSorensenKRyallsMRobinsonJThomasOLeonardJVImpaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol1993; 22:854–858.
12.
TawakolAOmlandTGerhardMWuJTCreagerMA.Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilatation in humans. Circulation1997; 95:1119–1121.
13.
ChambersJCMcGregorAJean-MarieJKoonerJS.Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet1998; 351:36–37.
14.
WilckenDELWilckenB.The pathogenesis of coronary artery disease: A possible role for methionine metabolism. J Clin Invest1976; 57:1079–1082.
15.
WilckenDELReddySGGuptaVJ.Homocysteinemia, ischemic heart disease, and the carrier state for homocystinuria. Metabolism1983; 32:363–370.
16.
DudmanNPBWilckenDELWangJLynchJFMaceyDLundbergGP.Disordered methionine homocystein metabolism in premature vascular disease: Its occurrence, cofactor therapy, and enzymology. Arterioscler Thromb1993; 13:512–516.
17.
WheelerDC.Cardiovascular disease in patients with chronic renal failure. Lancet1996; 348:1673–1674.
18.
WilckenDELGuptaVJ.Sulphur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulphide. Eur J Clin Invest1979; 9:301–307.
19.
WilckenDELGuptaVJBettsAK.Homocysteine in the plasma of renal transplant recipients: Effects of cofactors for methionine metabolism. Clin Sci1981; 61:743–749.
20.
WilckenDELDudmanNPBTyrrellPARobertsonMR.Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency; possible implications for the prevention of vascular disease. Metabolism1988; 37:697–701.
21.
BousheyCJBeresfordSAAOmennGSMotulskyAG.A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA1995; 274:1049–1057.
22.
GrahamIMDalyLERefsumHMRobinsonKBrattstromLEVelandPMPlasma homocysteine as a risk factor for vascular disease, the European concerted action project. JAMA1997; 277:1775–1781.
23.
NygardONordrehaugHRefsumHMUelandPMFarstadMVollsetSE.Plasma homocysteine levels and mortality in patients with coronary disease. N Engl J Med1997; 337:230–236.
24.
WilckenDELGuptaVJ.Cysteine-homocysteine mixed disulphide: Differing plasma concentrations in normal men and women. Clin Sci1979; 57:211–215.
25.
RobinsonKGuptaADennisVArheartKChaudharyDGreenRHyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation1996; 94:2743–2748.
26.
FrosstPBlomMJLiosRGoyettePSheppardCAMatthewsRA candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet1995; 10:111–113.
27.
WilckenDELWangXLSimASMcCredieRM.Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. Arterioscler Thromb Vasc Biol1996; 16:878–882.
28.
Van BockxmeerFMMamotteCDSVasikaranSDTaylorRR.Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation1997; 95:21–23.
29.
MaJStampferMJHennekensCHFrosstPSelhubJHorsfordJMethylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation1996; 94:2410–2416.
30.
NygardOVollsetSERefsumHStensvoldITverdalANordrehaugJTotal plasma homocysteine and cardiovascular risk profile. JAMA1995; 224:1526–1533.
31.
WilckenDELWilckenB.The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis1997; 20:295–300.
